EP0276485B1 - Dérivés dihydro de composés antibiotiques du type LL-E33288 - Google Patents

Dérivés dihydro de composés antibiotiques du type LL-E33288 Download PDF

Info

Publication number
EP0276485B1
EP0276485B1 EP87119344A EP87119344A EP0276485B1 EP 0276485 B1 EP0276485 B1 EP 0276485B1 EP 87119344 A EP87119344 A EP 87119344A EP 87119344 A EP87119344 A EP 87119344A EP 0276485 B1 EP0276485 B1 EP 0276485B1
Authority
EP
European Patent Office
Prior art keywords
formula
dihydro
compound
dihydro derivative
pseudoaglycone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP87119344A
Other languages
German (de)
English (en)
Other versions
EP0276485A3 (fr
EP0276485A2 (fr
Inventor
May Dean-Ming Lee
Michael Greenstein
David Paul Labeda
Amedeo Alexander Fantini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/004,153 external-priority patent/US4939244A/en
Priority claimed from US07/004,154 external-priority patent/US5037651A/en
Priority claimed from US07/009,321 external-priority patent/US4970198A/en
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Priority to EP01123067A priority Critical patent/EP1215212A3/fr
Publication of EP0276485A2 publication Critical patent/EP0276485A2/fr
Publication of EP0276485A3 publication Critical patent/EP0276485A3/fr
Application granted granted Critical
Publication of EP0276485B1 publication Critical patent/EP0276485B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/29—Micromonospora

Definitions

  • This invention relates to new antibacterial and antitumor agents designated pseudoaglycone and dihydro derivatives of LL-E33288 ⁇ 1 -I, LL-E33288 ⁇ 2 -I, LL-E33288 ⁇ 3 -I, LL-E33288 ⁇ 1 -I, LL-E33288 ⁇ 2 -I, LL-E33288 ⁇ 1 -I, and LL-E33288 ⁇ 1 -I, LL-E33288 ⁇ 1 -Br, LL-E33288 ⁇ 2 -Br, LL-E33288 ⁇ 3 -Br, LL-E33288 ⁇ 1 -Br, LL-E33288 ⁇ 2 -Br LL-E33288 ⁇ 1 -Br and LL-E33288 ⁇ 1 -Br to their production by fermentation, to methods for their recovery and concentration from crude solutions and to processes for their purification.
  • the present invention includes within its scope the anti-bacterial and
  • the LL-E33288 antibiotics are closely related compounds.
  • the fourteen antibiotics are recovered from fermentation and are initially obtained as a mixture, hereinafter either the LL-E33288 complex, the LL-E33288 Iodo-complex or the LL-E33288 Bromo-complex.
  • the iodine containing components of the LL-E33288 antibiotics are found only in fermentation using media containing inorganic or organic iodide while the bromine containing components (e.g., ⁇ 1 -Br, ⁇ 2 -Br, ⁇ 3 -Br, ⁇ 4 -Br, ⁇ 1 -Br, ⁇ 2 -Br, and ⁇ 1 -Br) are found only in fermentations using media containing inorganic or organic bromide.
  • LL-E33288 ⁇ 1 , LL-E33288 ⁇ 1 and LL-E33288 ⁇ 1 -I are generally the major components, together accounting for approximately 90% of the complex.
  • LL-E33288 ⁇ 1 , LL-E33288 ⁇ 2 , LL-E33288 ⁇ 3 , LL-E33288 ⁇ 4 and LL-E33288 ⁇ 2 are minor components, together accounting for approximately 10% of the complex.
  • the LL-E33288 antibiotics are active against gram-positive and gram-negative bacteria. Each of the components were also found to be active in a modification of the Biochemical Induction Assay [Elespuru, R. and Yarmolinsky, M., Environmental Mutagenesis, 1 , 65-78 (1978)], a test which specifically measures the ability of an agent to directly or indirectly initiate DNA damage.
  • Biochemical Induction Assay a test which specifically measures the ability of an agent to directly or indirectly initiate DNA damage.
  • both LL-E33288 ⁇ 1 -I and LL-E33288 ⁇ 1 -I were active at concentrations lower than 1x10 -6 mcg/ml.
  • E33288 X R R 2 R 4 ⁇ 2 I I H R 3 C 2 H 5 ⁇ 3 I I R 1 H ⁇ 1 I I R 1 R 3 (CH 3 ) 2 CH ⁇ 1 I I R 1 R 3 C 2 H 5 ⁇ 1 I I R 1 R 3 CH 3 ⁇ 1 Br Br R 1 R 3 (CH 3 ) 2 CH ⁇ 1 Br Br R 1 R 3 C 2 H 5 ⁇ 2 Br Br H R 3 C 2 H 5 ⁇ 3 Br Br R 1 H
  • the dihydro-LL-E33288-pseudoaglycone has the following proposed structure: and the following physico-chemical characteristics:
  • Vegetative growth from isolate UV 610(3) was prepared as employed for fermentation and used to inoculate a flask of medium consisting of peptone, dextrose, molasses and water.
  • the medium was supplemented with LL-E33288 ⁇ 1 -Br at a concentration of about 8 ⁇ g/ml.
  • a number of platings were done from this flask and a resistant population was obtained on the seventh day.
  • a total of 97 colonies (R1 to R97) were isolated.
  • Isolate R66 became NRRL-15975.
  • Isolate R80 is essentially similar to R66 in its biosynthetic potential.
  • Isolate R80 was then used as the starting culture from which a spore suspension was prepared and exposed to relatively high concentrations of the LL-E33288 complex, the purpose being to obtain isolates resistant to the LL-E33288 antibiotics and thereby improve production yields.
  • T 2 One survivor, labeled T 2 did produce greater yields of LL-E33288 ⁇ 1 -Br and LL-E33288 ⁇ 1 -I in flask fermentations.
  • a spore suspension of T 2 was prepared and exposed to UV-irradiation. A total of 131 colonies were then isolated (UV 703 to UV 834), fermented and assayed. From this group, isolate UV 784 was selected for its activity in flask fermentations. Isolate UV 784, when fermented in the iodine containing medium, produced approximately double the yield of R66 (NRRL-15975).
  • the mutant LL-E33288 UV 784 is maintained by that number in the culture collection of the Medical Research Division, American Cyanamid Company, Pearl River, New York.
  • a viable culture of this microorganism has been deposited with the Culture Collection Laboratory, Northern Regional Research Canter, U. S. Department of Agriculture, Peoria, Illinois on December 3, 1986, and has been added to its permanent collection. Access to said culture, under strain designation NRRL-18149, during pendency of the instant application shall be available to one determined by the Commissioner of Patents and Trademarks to be entitled thereto under C.F.R. ⁇ 1.14 and 35 U.S.C. ⁇ 122, and all restrictions on availability to the public of such culture will be irrevocably removed upon grant of a U. S. Patent on the instant application.
  • the present invention is not limited to this particular organisms or to organisms fully answering the above growth microscopic characteristics which were given for illustrative purposes only. In fact, it is desired and intended to include the use of mutants produced from these organisms by various means such as exposure to X-radiation, ultraviolet radiation, N '-methyl- N - nitro- N -nitrosoquanidine, actinophages and the like.
  • the in vitro antibacterial activity of dihydro LL-E33288gamma l-I was determined against a spectrum of gram-positive and gram-negative bacteria by a standard agar dilution method. Mueller-Hinton agar containing twofold decreasing concentrations of the antibiotics was poured into petri plates. The agar surfaces were inoculated with 1 to 5 x 10 4 colony forming units of bacteria by means of a Steers replicating device. The lowest concentration of LL-E33288 component that inhibited growth of a bacterial strain after about 18 hours of incubation at approximately 35°C was recorded as the minimal inhibitory concentration (MIC) for that strain. The results are summarized in Table II.
  • a compound as defined above for use in treating bacterial infections in warm-blooded animals is provided.
  • a compound as defined above for use in inhibiting the growth of tumors in a mammal is a compound as defined above for use in inhibiting the growth of tumors in a mammal.
  • a compound as defined above for use in regressing leukemia in a mammal A compound as defined above for use in regressing leukemia in a mammal.
  • composition of matter in unit dosage form comprising an antibacterially effective amount of a compound as defined above.
  • Cultivation of Micromonospora echinospora NRRL-15839 or NRRL-15975 may be carried out in a wide variety of liquid culture media.
  • Media which are useful for the production of these novel antibacterial and anti-tumor agents include an assimilable source of carbon, such as starch, sugar, molasses, glycerol, etc.; an assimilable source of nitrogen such as protein, protein hydrolysate, polypeptides, amino acids, corn steep liquor, etc.; and inorganic anions and cations, such as potassium, sodium, ammonium, calcium, sulfate, carbonate, phosphate, chloride, etc.
  • bromine sodium bromide
  • iodine potassium iodide
  • Trace elements such as boron, molybdenum, copper, etc., are supplied as impurities of other-constituents of the media.
  • Aeration in tanks and bottles is supplied by forcing sterile air through or onto the surface of the fermenting medium. Further agitation in tanks is provided by a mechanical impeller.
  • An antifoam agent such as silicone may be added as needed.
  • the LL-E33288 antibiotics are recovered from the fermentation broth by extracting the whole mash with an organic solvent such as ethyl acetate or dichloromethane.
  • the antibiotic complex, contained in the organic extract, is further purified by selective precipitation from lower hydrocarbons.
  • the crude LL-E33288 antibiotic complex thus obtained is further purified and separated into the individual components by a series of column chromatographies using silica gel, Sephadex® LH-20 (Pharmacia Fine Chemicals) and c 18 bonded silica.
  • a suspension containing spores and mycelia was prepared from a slant of Micromonospora echinospora ssp. calichensis , LL-E33288-UV 784 (NRRL-18149) by adding 5-8 ml of water and scraping the surface of the slant.
  • This suspension was used to inoculate 50 ml of a sterile medium of the following composition: Yeast extract 0.5% Beef extract 0.3% Tryptose 0.5% Dextrin 2.4% Dextrose 0.5% Calcium carbonate 0.4% Water qs 100%
  • the above medium in a 250 ml Erlenmeyer flask, was incubated at 28°C on a rotary shaker at 200 rpm for 3-4 days thus providing stage I inoculum.
  • Stage I inoculum was used to inoculate 50 ml of the same sterile medium in a 250 ml baffled flask and incubated at 28°C on a rotary shaker at 250 rpm for 2 days, thus providing stage II inoculum.
  • Stage II inoculum was used to inoculate 100 ml of sterile fermentation medium of the following composition: Sucrose 2.0% Ferrous sulfate heptahydrate 0.01% Magnesium sulfate heptahydrate 0.02% Calcium carbonate 0.25% Peptone 0.4% Molasses 0.25% Potassium iodide 0.01% Water qs 100%
  • the above medium in 500 ml baffled flasks was incubated at 28-30°C on a rotary shaker at 250 rpm for 6 days at which time the fermentation was harvested.
  • a three stage inoculum was prepared using a culture of LL-E33288-UV 784 (NRRL-18149).
  • the inoculum media were of the following formulation: Ingredient per/liter Calcium carbonate 4 g Hodag® FD 82 1 ml Dextrin 24 g Glucose 5 g Yeast extract 5 g Tryptone 5 g Beef extract 3 g Water qs
  • the first stage consisted of 100 ml of the above sterile medium in a 500 ml flask incubated at 32°C and 200 rpm for 2 days.
  • This first stage was used to inoculate a second stage consisting of 10 liters of the above sterile medium which was grown for 2 days at 32°C and 450 rpm in a small fermenter with a sterile air flow of one volume of air per volume of mash per minute (VVM).
  • This second stage was used to inoculate a third stage consisting of 300 liters of the above sterile medium which was grown for 2 days at 32°C, 200-250 rpm and a sterile air flow of 0.67 VVM in a tank fermenter.
  • a 150 liter portion of this stage III inoculum was used to inoculate a sterile 1500 liter fermentation medium of the following composition: Ingredient per/liter Sucrose 20.0 g Ferrous sulfate heptahydrate 0.1 g Magnesium sulfate heptahydrate 0.2 g Peptone 5.0 g Molasses 5.0 g Potassium iodide 0.5 g Calcium carbonate 5.0 g Hodag® FD 82 5.0 ml Water qs
  • the fermentation was carried out at 30°C, a sterile air flow of 0.75 VVM, a back pressure of 8 psig and agitation by an impeller driven at 120 rpm for 5-6 days at which time the mash was harvested.
  • the organic phase was separated, concentrated to 100 liters, adjusted to pH 6-7 with 2N sodium hydroxide and any aqueous phase discarded.
  • the organic phase was further concentrated to 20 liters and any aqueous phase and interfacial fats removed.
  • the organic phase was finally concentrated to a golden yellow syrup which was poured slowly into 7-8 times its volume of rapidly stirred hexane.
  • hexane insoluble gum containing the LL-E33288 antibiotics
  • the dried ethyl acetate solution was concentrated to a small volume and precipitated by the addition of ether and hexane, giving 53 g of crude LL-E33288 complex, containing 4.9 g of ⁇ 1 -I, 2.8 g of ⁇ 1 -I and small amounts of ⁇ 3 -I and ⁇ 1 -I.
  • a partially purified mixture of ⁇ 1 -I and ⁇ 1 -I (1.8 g, containing 648 mg of ⁇ 1 -I and 540 mg of ⁇ 1 -I) was chromatographed on a Woelm silica (32-63 ⁇ ) column (1.5 x 45 cm) packed and equilibrated with ethyl acetate. The column was eluted with ethyl acetate at 3 ml/minute for one hour, then the eluent was changed to ethyl acetate:methanol (97:3) and the elution was continued for 2 hours. Fractions of 15 ml were collected during the entire elution. Each fraction was analyzed as before and those containing pure ⁇ 1 -I were pooled and worked up to yield 367 mg of pure LL-E33288 ⁇ 1 -I.
  • Degradation products termed pseudaglycones, of LL-E33288, BBM-1675, FR-900405, FR-900406, PD 114759, PD 115028, CL-1577A, CL-1577B, CL-1577D, CL-1577E and CL-1724 antibiotics/antitumor agents are disclosed and described.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (13)

  1. Dérivé dihydrogéné de la pseudoaglycone iodée de LL-E33288 de formule :
    Figure 00510001
  2. Dérivé dihydrogéné de la pseudoaglycone bromée de LL-E33288 de formule :
    Figure 00510002
  3. Dérivé dihydrogéné de LL-E33288α2-Br de formule :
    Figure 00510003
    dérivé dihydrogéné de LL-E33288α3-Br de formule :
    Figure 00520001
    dérivé dihydrogéné de LL-E33288β1-Br de formule :
    Figure 00520002
    dérivé dihydrogéné de LL-E33288γ1-Br de formule :
    Figure 00520003
    dérivé dihydrogéné de LL-E33288α2-I de formule :
    Figure 00530001
    dérivé dihydrogéné de LL-E33288α3-I de formule :
    Figure 00530002
    dérivé dihydrogéné de LL-E33288β1-I de formule :
    Figure 00530003
    dérivé dihydrogéné de LL-E332888γ1-I de formule :
    Figure 00540001
    dérivé dihydrogéné de LL-E33288δ1-I de formule :
    Figure 00540002
  4. Antibiotique antitumoral LL-E33288 pouvant être obtenu, entre autres, par : fermentation aérobie d'un milieu liquide contenant des sources assimilables de carbone, d'azote, d'iode et de sels minéraux, ledit milieu ayant été inoculé avec une culture viable de l'organisme Micromonosporal echinospora ssp. calichensis mutant NRRL-18149 ou NRRL-15839 ou des mutants de NRRL-18149, jusqu'à ce qu'une activité antibiotique substantielle ait été conférée ; maintien de ladite culture en fermentation à une température d'environ 24-32°C pendant une durée d'environ 90-200 heures ; récolte de la trempe et récupération de l'antibiotique ; addition d'un iodure d'alkyle à une solution éthanolique de l'antibiotique ; refroidissement de la solution à la température d'un bain de glace ; addition d'une solution éthanolique de borohydrure de sodium ; décomposition du complexe de borate par addition d'acide acétique, précipitation dans une solution d'acétate d'éthyle par addition d'hexane et purification par chromatographie.
  5. Antibiotique antitumoral selon la revendication 4 appelé dihydro-LL-E33288-pseudoaglycone, ayant les caractéristiques physicochimiques suivantes :
    a) un poids moléculaire de 1052 (déterminé par spectrométrie de masse à bombardement d'atomes rapides) ;
    b) un spectre d'absorption ultraviolette tel que représenté sur la figure I (méthanol) ;
    c) un spectre d'absorption infrarouge tel que représenté sur la figure II (pastille de KBr) ;
    d) un spectre de résonance magnétique du proton tel que représenté sur la figure III (300 MHz, CDCl3) ; et
    e) spectre de résonance magnétique du carbone-13 tel que représenté sur la figure IV (75 MHz, CDCl3).
  6. Composé selon l'une quelconque des revendications précédentes à utiliser pour traiter des infections bactériennes chez les animaux à sang chaud.
  7. Composé selon l'une quelconque des revendications 1 à 5 à utiliser pour inhiber la croissance de tumeurs chez un mammifère.
  8. Composé selon l'une quelconque des revendications 1 à 5 à utiliser pour faire régresser la leucémie chez un mammifère.
  9. Utilisation d'un composé selon l'une quelconque des revendications 1 à 5 dans la fabrication d'un médicament pour traiter les infections bactériennes chez les animaux à sang chaud.
  10. Utilisation d'un composé selon l'une quelconque des revendications 1 à 5 dans la fabrication d'un médicament pour inhiber la croissance de tumeurs chez un mammifère.
EP87119344A 1987-01-30 1987-12-30 Dérivés dihydro de composés antibiotiques du type LL-E33288 Expired - Lifetime EP0276485B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP01123067A EP1215212A3 (fr) 1987-01-30 1987-12-30 Dérivés dihydro de composés antibiotiques du type LL-E33288

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US9321 1987-01-30
US4153 1987-01-30
US07/004,153 US4939244A (en) 1987-01-30 1987-01-30 Pseudoaglycones of LL-E33288 antibiotics
US07/004,154 US5037651A (en) 1987-01-30 1987-01-30 Dihydro derivatives of LL-E33288 antibiotics
US07/009,321 US4970198A (en) 1985-10-17 1987-01-30 Antitumor antibiotics (LL-E33288 complex)
US4154 1987-01-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP01123067A Division EP1215212A3 (fr) 1987-01-30 1987-12-30 Dérivés dihydro de composés antibiotiques du type LL-E33288
EP01123067.9 Division-Into 2001-09-26

Publications (3)

Publication Number Publication Date
EP0276485A2 EP0276485A2 (fr) 1988-08-03
EP0276485A3 EP0276485A3 (fr) 1990-09-12
EP0276485B1 true EP0276485B1 (fr) 2002-06-12

Family

ID=27357575

Family Applications (2)

Application Number Title Priority Date Filing Date
EP87119344A Expired - Lifetime EP0276485B1 (fr) 1987-01-30 1987-12-30 Dérivés dihydro de composés antibiotiques du type LL-E33288
EP01123067A Withdrawn EP1215212A3 (fr) 1987-01-30 1987-12-30 Dérivés dihydro de composés antibiotiques du type LL-E33288

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP01123067A Withdrawn EP1215212A3 (fr) 1987-01-30 1987-12-30 Dérivés dihydro de composés antibiotiques du type LL-E33288

Country Status (6)

Country Link
EP (2) EP0276485B1 (fr)
JP (2) JP2791028B2 (fr)
AT (1) ATE219096T1 (fr)
DE (1) DE3752355T2 (fr)
ES (1) ES2177518T3 (fr)
SG (1) SG52432A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079233A (en) * 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
EP0330874A3 (fr) * 1988-02-29 1989-10-18 American Cyanamid Company Agents antibactériens et antitumoraux LL-E33288 epsilon-I et LL-E33288-epsilon-Br, avec les procédés et intermédiaires pour obtention desdits agents
IL115770A (en) * 1989-04-14 1999-03-12 American Cyanamid Co Substituted disulfides of formula q-sp-ss-w their preparation and use for inhibiting the growth of tumours and for treating bacterial infections
AU2011260035B2 (en) * 2010-06-04 2016-03-03 Threadless Closures Limited Closure for a container
JP6077975B2 (ja) * 2013-09-30 2017-02-08 ヤンマー株式会社 軸受構造および作業車両

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3588213T2 (de) * 1984-11-16 1999-09-30 American Cyanamid Co Antitumorale Antibiotika (Komplex LL-E-33288)
IL79519A0 (en) * 1985-08-27 1986-10-31 Bristol Myers Co Bbm-1675c and d antitumor antibiotics

Also Published As

Publication number Publication date
EP0276485A3 (fr) 1990-09-12
EP1215212A2 (fr) 2002-06-19
DE3752355D1 (de) 2002-07-18
JPS63216494A (ja) 1988-09-08
JP2791028B2 (ja) 1998-08-27
EP0276485A2 (fr) 1988-08-03
JP3130270B2 (ja) 2001-01-31
ES2177518T3 (es) 2002-12-16
EP1215212A3 (fr) 2003-05-21
SG52432A1 (en) 1998-09-28
DE3752355T2 (de) 2002-12-05
ATE219096T1 (de) 2002-06-15
JPH1057093A (ja) 1998-03-03

Similar Documents

Publication Publication Date Title
US4970198A (en) Antitumor antibiotics (LL-E33288 complex)
US5108912A (en) Antitumor antibiotics (LL-E33288 complex)
US4007167A (en) Antibiotic BM123 and production thereof
GB1589536A (en) Antitumor anthracycline antibiotics
JPH0689017B2 (ja) Ｂｂｍ−２４７８ｂ抗生物質
EP0182152B1 (fr) Antibiotiques antitumoraux (complexe LL-E33288)
EP0276485B1 (fr) Dérivés dihydro de composés antibiotiques du type LL-E33288
US5618809A (en) Indolocarbazoles from saccharothrix aerocolonigenes copiosa subsp. nov SCC 1951 ATCC 53856
EP0171677B1 (fr) Antibiotiques du type anthracycline
EP0110155B1 (fr) Dérivés d'anthracycline, leur méthode de préparation à partir d'une souche de microorganismes, la nouvelle souche streptomyces cyaneus, et l'emploi de ces dérivés d'anthracycline comme médicaments
EP1001957B1 (fr) Macrolides possedant une activite anti-tumorale
EP0275966B1 (fr) Un dérivé de doxorubicine, un procédé pour sa préparation, ses compositions pharmaceutiques et son utilisation dans la production de médicaments
JP2504450B2 (ja) ダウノルビシンに関連した新規生合成アントラサイクリン
EP0702691B1 (fr) Nouveau thiodepsipeptide isole d'un actinomycete marin
US4939244A (en) Pseudoaglycones of LL-E33288 antibiotics
JP2793826B2 (ja) 抗菌および抗腫瘍剤ＬＬ―Ｅ３３２８８ε―ＩおよびＬＬ―Ｅ３３２８８ε―Ｂｒ、前記剤を生産する方法および中間体
US4743594A (en) Antibiotic, antitumor compounds and their use
US4774184A (en) Culture and process for producing antibiotic LL-D42067alpha
US4572895A (en) Process for preparing an antibiotic complex by culturing actinomyces strain ATCC 39417
JPS62238298A (ja) 新規アントラサイクリン抗生物質ｄｃｐ−１及び２
CA1138358A (fr) Antibiotique bm782 antibacterien
EP0399505B1 (fr) Composés SN-198C physiologiquement actifs, méthode et bactéries pour leur préparation
EP0423247B1 (fr) Composes de coumamidine
JPH05117288A (ja) 新規アントラサイクリン系抗生物質
GB2187732A (en) 13-(S)-dihydro-13-O-B-D-glucopyranoside of anthracyclinones

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB GR IT LI NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB GR IT LI NL SE

17P Request for examination filed

Effective date: 19901221

17Q First examination report despatched

Effective date: 19910918

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AMERICAN CYANAMID COMPANY

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE ES FR GB GR IT LI NL SE

REF Corresponds to:

Ref document number: 219096

Country of ref document: AT

Date of ref document: 20020615

Kind code of ref document: T

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07H 15/203 A, 7C 12P 19/44 B, 7A 61K 31/70 B, 7C 12N 1/20 B, 7C 12P 19/00 J, 7C 12R 1:29 J

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

REF Corresponds to:

Ref document number: 3752355

Country of ref document: DE

Date of ref document: 20020718

ET Fr: translation filed
REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20020403066

Country of ref document: GR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2177518

Country of ref document: ES

Kind code of ref document: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: WYETH HOLDINGS CORPORATION

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: WYETH HOLDINGS CORPORATION

Free format text: AMERICAN CYANAMID COMPANY#ONE CYANAMID PLAZA#WAYNE, NJ 07470-8426 (US) -TRANSFER TO- WYETH HOLDINGS CORPORATION#FIVE GIRALDA FARMS#MADISON, NJ 07940 (US)

26N No opposition filed

Effective date: 20030313

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: WYETH HOLDINGS CORPORATION

NLS Nl: assignments of ep-patents

Owner name: WYETH HOLDINGS CORPORATION

REG Reference to a national code

Ref country code: FR

Ref legal event code: CD

Ref country code: FR

Ref legal event code: CA

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20051024

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20051104

Year of fee payment: 19

Ref country code: AT

Payment date: 20051104

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20051109

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20051201

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20051202

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20051216

Year of fee payment: 19

Ref country code: ES

Payment date: 20051216

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20051230

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20060113

Year of fee payment: 19

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061231

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061231

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061231

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061231

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20061231

Year of fee payment: 20

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070703

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20061230

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20070701

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20070831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061230

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061230

BERE Be: lapsed

Owner name: *WYETH HOLDINGS CORP.

Effective date: 20061231

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20070102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070102

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070704